MS3
MCID: MLT094
MIFTS: 28

Multiple Sclerosis 3 (MS3)

Categories: Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Multiple Sclerosis 3

MalaCards integrated aliases for Multiple Sclerosis 3:

Name: Multiple Sclerosis 3 57 74
Multiple Sclerosis, Susceptibility to, 3 57 13
Ms3 57 74

Classifications:



External Ids:

MeSH 44 D009103
MedGen 42 C2675477

Summaries for Multiple Sclerosis 3

UniProtKB/Swiss-Prot : 74 Multiple sclerosis 3: A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheath, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease.

MalaCards based summary : Multiple Sclerosis 3, also known as multiple sclerosis, susceptibility to, 3, is related to multiple sclerosis and triiodothyronine receptor auxiliary protein. An important gene associated with Multiple Sclerosis 3 is MS3 (Multiple Sclerosis, Susceptibility To, 3), and among its related pathways/superpathways are Pathways in cancer and JAK-STAT signaling pathway (KEGG). Affiliated tissues include monocytes, testes and brain.

More information from OMIM: 612595 PS126200

Related Diseases for Multiple Sclerosis 3

Graphical network of the top 20 diseases related to Multiple Sclerosis 3:



Diseases related to Multiple Sclerosis 3

Symptoms & Phenotypes for Multiple Sclerosis 3

Clinical features from OMIM:

612595

Drugs & Therapeutics for Multiple Sclerosis 3

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Use of Two DBS Electrodes to Treat Post-Traumatic Tremor Completed NCT00954421
2 The Validity and Reliability of 3 Meter Backwards Walk Test in Multiple Sclerosis Patients Recruiting NCT04004026

Search NIH Clinical Center for Multiple Sclerosis 3

Genetic Tests for Multiple Sclerosis 3

Anatomical Context for Multiple Sclerosis 3

MalaCards organs/tissues related to Multiple Sclerosis 3:

41
Monocytes, Testes, Brain, Spinal Cord

Publications for Multiple Sclerosis 3

Articles related to Multiple Sclerosis 3:

(show top 50) (show all 51)
# Title Authors PMID Year
1
Interleukin-7 receptor alpha gene polymorphism influences multiple sclerosis risk in Asians. 8
21670443 2011
2
Risk alleles for multiple sclerosis in multiplex families. 8
19506219 2009
3
Use of a genetic isolate to identify rare disease variants: C7 on 5p associated with MS. 8
19221116 2009
4
IL7RA polymorphisms and susceptibility to multiple sclerosis. 8
18272905 2008
5
Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. 8
17660816 2007
6
Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. 8
17660817 2007
7
Risk alleles for multiple sclerosis identified by a genomewide study. 8
17660530 2007
8
Occipital neuralgia associates with high cervical spinal cord lesions in idiopathic inflammatory demyelinating disease. 38
29629601 2019
9
Medial Gamma Knife thalamotomy for intractable pain. 38
30544296 2018
10
Pharmacogenomics of Chemically Distinct Classes of Keap1-Nrf2 Activators Identify Common and Unique Gene, Protein, and Pathway Responses In Vivo. 38
29367259 2018
11
[Bladder cancer in neurogenic patients: A retrospective study of management and follow-up]. 38
29174817 2018
12
Clinical Characteristics and Ancillary Test Results Among Patients With Botulism-United States, 2002-2015. 38
29293936 2017
13
Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study. 38
28129749 2017
14
Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. 38
27461166 2016
15
Associations of Systemic Diseases with Intermediate Uveitis. 38
26786193 2016
16
A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging. 38
25681411 2015
17
Why are prions and amyloid structures immune suppressive and other intriguing questions facing neuroimmunologists in the future. 38
25193013 2014
18
Dilated Virchow-Robin spaces and multiple sclerosis: 3 T magnetic resonance study. 38
24297592 2014
19
Influence of drugs on gap junctions in glioma cell lines and primary astrocytes in vitro. 38
24904426 2014
20
Central nervous system inflammatory demyelinating disorders among Hong Kong Chinese. 38
23838529 2013
21
Pathogenesis of pediatric multiple sclerosis. 38
22952316 2012
22
[Magnetic resonance spectroscopy-guided stereotactic biopsy for brain lesion]. 38
23302459 2012
23
Focal cortical lesion detection in multiple sclerosis: 3 Tesla DIR versus 7 Tesla FLASH-T2. 38
22045554 2012
24
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. 38
20028707 2010
25
Matrix metalloproteinases involvement in pathologic conditions. 38
20495735 2010
26
Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods. 38
19216837 2009
27
Multiple sclerosis: interferon beta for some serious forms. 38
18092425 2007
28
Therapeutic plasma exchange in the treatment of neuroimmunologic disorders: review of 50 cases. 38
17224307 2007
29
Acute disseminated encephalomyelitis: a follow-up study in Taiwan. 38
17028121 2007
30
[The application of botulinum toxin type A in the treatment of spastic paraparesis]. 38
17953270 2007
31
Diagnostic value of prolonged latencies in the vestibular evoked myogenic potential. 38
11556854 2001
32
Clinical utility of magnetic corticospinal tract stimulation at the foramen magnum level. 38
8647038 1996
33
Periodic lateralized epileptiform discharges in multiple sclerosis. 38
8689994 1996
34
Intermediate uveitis: what is the natural course of the disease and its relationship with other systemic diseases? 38
7711475 1994
35
Lacunar syndromes due to non ischaemic causes: prevalence and clinical findings (study of 19 patients). 38
8160550 1993
36
Acute radicular pain as a presenting symptom in multiple sclerosis. 38
1536627 1992
37
[A clinical study of voiding status in multiple sclerosis patients]. 38
2011964 1991
38
Trigemino-cervical reflex in pathology of the brain stem and of the first cervical cord segments. 38
2707142 1989
39
[Cerebrospinal fluid proteins form the colloidal benzoin reaction to the present: a study of intrathecal immunity]. 38
3055164 1988
40
Evoked potentials in multiple sclerosis before and after high-dose methylprednisolone infusion. 38
3940867 1986
41
[Usefulness of cerebrospinal fluid in patients with sciatica]. 38
6398503 1984
42
[Changes in fibronectin concentration during therapeutic plasmapheresis. Therapeutic effectiveness of selective removal of fibronectin in immune complex pathology]. 38
6236575 1984
43
[Asymptomatic multiple sclerosis - 3 cases (author's transl)]. 38
7339773 1981
44
Familial multiple sclerosis: clinical, histocompatibility, and viral serological studies. 38
418737 1978
45
[Immunosuppressive treatment of multiple sclerosis. 3. Results of treatment with azathioprine and antilymphocytic globulin (author's transl)]. 38
4216823 1974
46
[Multiple sclerosis. 3. Gliotoxic factors]. 38
4916239 1970
47
[Advanced forms of multiple sclerosis; 3 anatomo-clinical observations, 2 presenting amyotrophia and absent tendon reflexes]. 38
5459720 1970
48
The management of multiple sclerosis. 3. Apparent suppression of symptoms by an estrogen-progestin compound. 38
5766630 1969
49
[Studies on the seasonal incidence of multiple sclerosis. 3. Comparison of seasonal incidence in four Swiss regions]. 38
5686566 1968
50
Studies on the natural history of multiple sclerosis. 3. Epidemiologic analysis of the army experience in World War II. 38
5333273 1967

Variations for Multiple Sclerosis 3

Expression for Multiple Sclerosis 3

Search GEO for disease gene expression data for Multiple Sclerosis 3.

Pathways for Multiple Sclerosis 3

Pathways related to Multiple Sclerosis 3 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.98 IL7R IL12B
2
Show member pathways
11.32 IL7R IL12B
3
Show member pathways
11.17 IL7R IL12B
4 10.57 IL7R IL12B

GO Terms for Multiple Sclerosis 3

Cellular components related to Multiple Sclerosis 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.62 IL7R IL12B

Biological processes related to Multiple Sclerosis 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 8.96 IL7R IL12B
2 cell surface receptor signaling pathway GO:0007166 8.62 IL7R IL12B

Molecular functions related to Multiple Sclerosis 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine receptor activity GO:0004896 8.62 IL7R IL12B

Sources for Multiple Sclerosis 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....